acquisition

The acquisition became effective on 31 July 2026 and builds on a long-standing partnership between the two companies.

Acceptances covering 10.7 million shares were received before the offer period closed on 30 July.

This strengthens Germany’s premium pet food market presence

The acquisition builds on Boehringer Ingelheim’s broader investment in therapeutic vaccines.

Novonesis has not disclosed an expected closing date.

The acquisition adds a leading, clinically studied muscle health brand and its patented Fortetropin® ingredient technology to PetIQ.

The official branch will streamline the delivery of premium genetics and hands-on agronomic support to Korean farmers.

Verax™ was first introduced for broilers, where it has been credited with enhancing decision-making and reducing reliance on antibiotics.

Financial details of the transaction were not disclosed.

The deal is expected to accelerate the global deployment of TARGAN’s hatchery automation and biodevice solutions.